Clinical Trial Update: Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a single oral dose of PBF-680 to attenuate airway hyperresponsiveness in mild-to-moderate asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PBF-680

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Asthma | Phase 2 | Status: COMPLETED